Hyperkalaemia in the Cardiorenal Patient - Navigating Guidelines & Real-World Data

Published: 21 June 2024

  • Views:

    Views Icon 235
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Dr Anjay Rastogi and Dr Clara Bonanad discuss the evolving management strategies of hyperkalaemia in heart failure and chronic kidney disease, in this short video series. In this three part discussion they cover the most recent guidelines from ACC, ESC and KDIGO, real-world evidence from the recent ZORA trials and the use of novel potassium binders in optimising guideline directed medical therapy. 

This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall current guidance and consensus for management of hyperkalaemia
  • Gain insight into the real-world use of novel potassium binders in hyperkalaemia
  • Identify common barriers to optimal RAASi blockade and adoption of evidence-based novel potassium binders

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Nephrologists
  • Primary Care Physicians

More from this programme

Part 1

Consolidating RAASi Recommendations in recent HF and CKD Guidelines

Dr Anjay Rastogi and Dr Clara Bonanad open this video series by discussing the importance of RAASi continuation in cardiorenal disease. They also cover the most recent guidelines from ESC, ACC/AHA and KDIGO on hyperkalaemia management and summarise the best practice messages.

Part 2

Emerging Data in Hyperkalaemia - Insights from Real-World Practice

In this second part, Dr Bonanad invites Dr Rastogi to present key data from the observational ZORA study on hyperkalaemia management and RAASi use in real world practice.

Part 3

Optimising RAASi GDMT with Novel Potassium Binders

In this final part, Dr Rastogi and Dr Bonanad discuss the STRONG-HF study and how novel hyperkalaemia management strategies with potassium binders can be used to achieve optimal guideline directed medical therapy in heart failure and CKD.

About the episode

Dr Anjay Rastogi and Dr Clara Bonanad open this video series by discussing the importance of RAASi continuation in cardiorenal disease. They also cover the most recent guidelines from ESC, ACC/AHA and KDIGO on hyperkalaemia management and summarise the best practice messages.

Faculty Biographies

Anjay  Rastogi

Anjay Rastogi

Professor and Clinical Chief of Nephrology

Dr Anjay Rastogi is Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine UCLA in Los Angeles, California. Dr Rastogi is recognised as a pioneer in the early treatment of chronic kidney disease to prevent patients’ need to transition to dialysis.

Dr Rastogi is board-certified in Nephrology and has a doctoral degree (PhD) in Pharmacology. He did his Internal Medicine residency and Nephrology fellowship at UCLA; he completed his graduate training under the mentorship of Nobel Laureate Professor Louis Ignarro, also at UCLA. Dr Rastogi is the founding Director of the UCLA Health CORE Kidney Programme. This Programme is based on the CORE values of Clinical Excellence, Outreach, Research, and Education.

 

 

 

View full profile
Clara  Bonanad Lozano

Clara Bonanad Lozano

Dr Clara Bonanad Lozano is a cardiologist at the University Clinical Hospital of Valencia, ES and president of the Association of Geriatric Cardiology of the Spanish Society of Cardiology. Her clinical interests are Myocardial Infarction, Echocardiography, Pacemakers, Cardiac Imaging, Diabetes, Cardiovascular, and Heart Failure.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.